BÜHLMANN Calprotectin Assay Citations – Page 4 – Buhlmann Diagnostics Corp

Category: BÜHLMANN Calprotectin Assay Citations

A number of the publications in the citation list describe applications that are outside of product claims thus they should be used for information only.

Do Not Forget About Pre-Analytics in Faecal Calprotectin Measurement!

BÜHLMANN fCAL® turbo and CALEX® Cap: Oyaert, M., Van den Bremt, S. et al. Do not forget about pre-analytics in faecal calprotectin measurement! Clinica Chimica Acta. 2017 Oct; 473:124-126. doi:10.1016/j.cca.2017.08.025. PMID: 28847684 . Highlights from this Publication This study found an optimal stability of fecal calprotectin when sampled with CALEX® extraction buffer and stored at 2-8 °C for 7 days. Furthermore, the
Continue Reading

Diagnostic Accuracy of Fecal Calprotectin in Assessing the Severity of Inflammatory Bowel Disease: From Laboratory to Clinic

BÜHLMANN fCAL® ELISA: S. Moein, D. Quujeq et al. Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. Caspian J Intern Med 2017; 8(3):178-182 DOI: 10.22088/cjim.8.3.178. Highlights from this Publication “ The current study also suggested 78.4 µg/g as the cut-off level for FC by 100% sensitivity and
Continue Reading

Turbidimetric Determination of Fecal Calprotectin Using Two Table Top Chemistry Analyzers: Mindray BS-200E and Cobas® c111

BÜHLMANN fCAL® turbo: Mandic-Havelka, A. Nilsen, T. et. al. Turbidimetric Determination of Fecal Calprotectin Using Two Table Top Chemistry Analyzers: Mindray BS-200E and Cobas® c111.  Clin Lab.  2017 May 1;63(5):907-913. doi: 10.7754/Clin.Lab.2016.161032.  PMID: 28627817 Highlights from this Publication “The assay was linear in the range between 20 and 1,900 µg/g with a limit of quantification around 20
Continue Reading

Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity

IBDoc® Citation: Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF, Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity, Clinical Gastroenterology and Hepatology (2017) Jun 9. pii: S1542-3565(17)30712-7. DOI:10.1016/j.cgh.2017.06.007,  PMID:28606846. Highlights from this Publication “… we showed that the smartphone reader used by patients
Continue Reading

Usability of a Home-Based Test for the Measurement of Fecal Calprotectin in Asymptomatic IBD Patients Digestive and Liver Disease

IBDoc® Citation: Bello C, Roseth A, Guardiola J, Reenaers C, Ruiz-Cerulla A, Kemseke C Van, Arajol C, Reinhard C, Seidel L, Louis E.Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Digestive and Liver Disease. 2017 May 19. pii: S1590-8658(17)30886-1. http://dx.doi.org/10.1016/j.dld.2017.05.009 PMID: 28587751 Highlights from this Publication “ …Globally, the correlation between
Continue Reading

Correlation of Rapid Point-of-Care vs Send-Out Fecal Calprotectin Monitoring in Pediatric Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL extended Citation: Rodriguez, A. et al.  Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease. World J Gastrointest Pharmacol Ther 8(2):127-130. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.127. Highlight from this Publication “In summary, we present the first correlation study of rapid POC calprotectin testing in a pediatric IBD
Continue Reading

Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide

BÜHLMANN fCAL® ELISA: Heidi A, Park KT, Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis. 2017 Jun;23(6):894-902. doi: 10.1097/MIB.0000000000001082. PMID: 28511198 Highlights from this Publication “This systematic review shows that the relapsing remitting nature of IBD becomes less unpredictable
Continue Reading

Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation: Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780. Highlights from this Publication “In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who
Continue Reading

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory BowelDisease Can J Gastroenterol Hepatol. 2016;2016:2483261. Epub 2016 Sep 28.DOI:10.1155/2016/2483261.  PMID: 27774443.  This Canadian study represents how FCAL testing is utilized in the field for monitoring disease activity in IBD.  The reference for the cut-off
Continue Reading

Proactive Therapeutic Drug Monitoring of Infliximab: A Comparative Study of a New Point-of-Care Quantitative Test with Two Established ELISA Assays

BÜHLMANN Quantum Blue® Infliximab Trough Level Assay Citation: Afonso J, Lopes S et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92. doi: 10.1111/apt.13757. Epub 2016 Aug 10. PMID: 27507790 First Publication using our Quantum Blue® Infliximab Trough Level Assay We are very
Continue Reading